Analysts Issue Forecasts for Humacyte FY2028 Earnings

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for shares of Humacyte in a research note issued on Tuesday, November 5th. HC Wainwright analyst V. Bernardino expects that the company will post earnings of $0.71 per share for the year. HC Wainwright currently has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Humacyte's current full-year earnings is ($1.09) per share.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04).

HUMA has been the topic of a number of other research reports. BTIG Research reiterated a "buy" rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. TD Cowen reaffirmed a "buy" rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Piper Sandler set a $6.00 target price on Humacyte and gave the stock a "neutral" rating in a report on Friday, October 18th. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. Finally, Benchmark reiterated a "buy" rating and issued a $15.00 price target on shares of Humacyte in a research note on Thursday, October 10th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $11.00.

Humacyte Trading Up 4.0 %

Shares of HUMA traded up $0.21 during trading hours on Wednesday, hitting $5.43. The company had a trading volume of 4,282,239 shares, compared to its average volume of 2,345,469. The firm has a market cap of $648.07 million, a P/E ratio of -4.31 and a beta of 1.47. Humacyte has a 52-week low of $2.08 and a 52-week high of $9.97. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61. The stock's 50 day moving average price is $5.49 and its 200 day moving average price is $6.12.

Insider Buying and Selling

In related news, CEO Laura E. Niklason sold 277,090 shares of Humacyte stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the transaction, the chief executive officer now directly owns 4,029,374 shares of the company's stock, valued at $26,070,049.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, Director Brady W. Dougan sold 252,676 shares of the firm's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the transaction, the director now owns 4,306,464 shares in the company, valued at $28,896,373.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Laura E. Niklason sold 277,090 shares of the firm's stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total value of $1,792,772.30. Following the completion of the transaction, the chief executive officer now owns 4,029,374 shares of the company's stock, valued at approximately $26,070,049.78. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,084,153 shares of company stock valued at $6,869,996 over the last quarter. 11.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Humacyte

Several hedge funds have recently bought and sold shares of HUMA. Victory Capital Management Inc. raised its holdings in Humacyte by 551.6% in the 3rd quarter. Victory Capital Management Inc. now owns 76,896 shares of the company's stock worth $418,000 after purchasing an additional 65,095 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in Humacyte during the third quarter worth $75,000. China Universal Asset Management Co. Ltd. raised its position in Humacyte by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company's stock valued at $125,000 after purchasing an additional 8,965 shares during the period. Private Advisor Group LLC boosted its stake in Humacyte by 1.8% during the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company's stock worth $2,030,000 after buying an additional 6,510 shares during the period. Finally, Wealth Effects LLC purchased a new stake in shares of Humacyte in the 3rd quarter valued at approximately $349,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.